Explore OXB's Innovative Webinar on Viral Vector Manufacturing
Join OXB for an Insightful Webinar on Viral Vectors
OXB, renowned for its commitment to quality and innovation in the cell and gene therapy sector, is hosting a free and informative webinar that focuses on the acceleration of viral vector drug product development using advanced robotics. This webinar promises to be a valuable opportunity for professionals interested in the future of viral vector manufacturing.
Webinar Details and Agenda
Titled "Accelerating Viral Vector Manufacturing: The Use of Automation from Early Stage to QC Release", this 60-minute session will take place on an upcoming date at a schedule that's convenient for various time zones. Attendees can expect to see how automation streamlines the production process while improving quality and efficiency.
Featured Speakers Bring Expertise
The webinar will feature leading experts from OXB, including:
- André Raposo, PhD, Director of the Innovation Department
- Gareth McCathie, PhD, Group Lead of the Innovation Department
- Thomas Evans, Principal Scientist in the Innovation Department
These experts will share their insights on the pioneering automation techniques employed in viral vector manufacturing, shining a light on how digital tools are revolutionizing production processes and analytical workflows.
Focus on Innovation and Case Studies
During the presentations, attendees will be treated to case studies showcasing transfection optimization and how automated analytical methods such as qPCR, ELISA, and cell-based assays are implemented to enhance production quality. The speakers will provide real-world examples to illustrate their points, making this session particularly engaging.
Engage with Experts in Live Q&A
After the presentations, a live Q&A session will allow participants to ask questions directly to the experts, facilitating an engaging discussion about the latest trends and challenges in viral vector manufacturing.
About OXB's Legacy and Expertise
OXB (LSE: OXB) stands as a leading contract development and manufacturing organization (CDMO) specializing in cell and gene therapies. For over 25 years, OXB has been at the forefront of viral vector technology, collaborating with some of the most innovative pharmaceutical and biotechnology companies worldwide. The organization is dedicated to empowering its clients with the capabilities needed to deliver transformative therapies to patients everywhere.
OXB's extensive experience encompasses a wide array of viral vector types, including lentivirus, adeno-associated virus (AAV), and adenovirus. They pride themselves on providing robust quality-assurance systems and adhering to stringent regulatory standards, ensuring that their clients' products meet the highest benchmarks.
OXB's Cutting-Edge Technology
One notable innovation from OXB is the TetraVecta™ system, a fourth-generation lentiviral vector platform designed to enhance production capabilities. Additionally, OXB employs dual plasmid systems for AAV production, supplemented by advanced processes such as suspension and perfusion. These methodologies aim to optimize production efficiency and yield high-quality viral vectors.
Connect with OXB
As a recognized leader in the field, OXB also appreciates the importance of community engagement and ongoing dialogue. Whether industry professionals or interested parties, everyone can learn more about OXB's contributions toward advancing healthcare through innovative solutions.
For further inquiries about the webinar, interested parties can reach out directly to OXB's Chief Business Officer, Sebastien Ribault. Their contact details are available for seamless communication.
Frequently Asked Questions
What will be covered in the OXB webinar?
The webinar will focus on the use of automation in viral vector manufacturing processes and include case studies demonstrating its real-world applications.
Who are the speakers at the webinar?
Expert speakers from OXB's Innovation Department will present, sharing their vast knowledge and experiences in viral vector manufacturing.
How can I register for the webinar?
Participants can register for the webinar through OXB's official website or the provided registration link.
What are the benefits of attending this webinar?
Attendees will gain insights into the latest technological advancements in viral vector manufacturing and have the opportunity to engage with industry experts.
Is there a cost associated with the webinar?
No, the webinar is free to attend, making it accessible for all interested professionals.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
